Frontiers in medicine · 2026
Effects of topical Averrhoa bilimbi leaf extract cream on IL-22 and filaggrin in a murine model of atopic dermatitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hazlianda Cut Putri, Sari Pane Yunita, Lubis Ramona Duma Sari, Rambe Andrina Yunita Murni, Djawad Khairuddin, Laksmi Lidya Imelda, Amin Mustafa Mahmud, Restimulia Lia
Аннотация
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by immune dysregulation and impaired epidermal barrier function. Interleukin-22 (IL-22) contributes to epidermal inflammation and disrupts keratinocyte differentiation, whereas filaggrin is essential for maintaining epidermal barrier integrity. Averrhoa bilimbi leaves contain phytochemical constituents with potential anti-inflammatory activity, but their effects on IL-22 and filaggrin expression in AD remain unclear.
OBJECTIVE: To evaluate the effects of topical A. bilimbi leaf ethanolic extract cream (ABLEC) on skin-tissue IL-22 concentrations and filaggrin expression in a 2,4-dinitrofluorobenzene- and ovalbumin-induced murine model of AD.
METHODS: This randomized posttest-only controlled animal study included 30 male BALB/c mice allocated to six groups (n = 5/group): vehicle control, positive control treated with 0.1% betamethasone valerate, untreated AD control, and ABLEC at 0.01%, 0.02%, and 0.04%. AD-like inflammation was induced with dinitrofluorobenzene and ovalbumin for 28 days. Assigned topical preparations were subsequently applied at 42 mg to a 6-cm2 dorsal skin area every 12 h for 14 days. Cutaneous IL-22 levels were measured by enzyme-linked immunosorbent assay, whereas filaggrin expression was assessed immunohistochemically and quantified using ImageJ. IL-22 data were analyzed using the Kruskal-Wallis test followed by Dunn's post-hoc test with Benjamini-Hochberg false-discovery-rate correction; filaggrin expression was analyzed using one-way ANOVA.
RESULTS: Cutaneous IL-22 concentrations differed significantly among groups (Kruskal-Wallis = 12.927, p = 0.024; ε 2 = 0.330). The vehicle control, positive control, ABLEC 0.02%, and ABLEC 0.04% groups showed significantly lower IL-22 concentrations than the untreated AD control (adjusted p = 0.024 for each). However, none of the ABLEC groups differed significantly from the vehicle control, indicating that an extract-specific effect could not be demonstrated. Filaggrin expression did not differ significantly among groups (p = 0.547; ω 2 = 0.000).
CONCLUSION: ABLEC at 0.02% and 0.04% were associated with lower cutaneous IL-22 concentrations than the untreated AD control, but similar reductions in the vehicle control precluded demonstration of an extract-specific effect. Furthermore, no statistically detectable difference in filaggrin expression or dose-response relationship was observed.
OBJECTIVE: To evaluate the effects of topical A. bilimbi leaf ethanolic extract cream (ABLEC) on skin-tissue IL-22 concentrations and filaggrin expression in a 2,4-dinitrofluorobenzene- and ovalbumin-induced murine model of AD.
METHODS: This randomized posttest-only controlled animal study included 30 male BALB/c mice allocated to six groups (n = 5/group): vehicle control, positive control treated with 0.1% betamethasone valerate, untreated AD control, and ABLEC at 0.01%, 0.02%, and 0.04%. AD-like inflammation was induced with dinitrofluorobenzene and ovalbumin for 28 days. Assigned topical preparations were subsequently applied at 42 mg to a 6-cm2 dorsal skin area every 12 h for 14 days. Cutaneous IL-22 levels were measured by enzyme-linked immunosorbent assay, whereas filaggrin expression was assessed immunohistochemically and quantified using ImageJ. IL-22 data were analyzed using the Kruskal-Wallis test followed by Dunn's post-hoc test with Benjamini-Hochberg false-discovery-rate correction; filaggrin expression was analyzed using one-way ANOVA.
RESULTS: Cutaneous IL-22 concentrations differed significantly among groups (Kruskal-Wallis = 12.927, p = 0.024; ε 2 = 0.330). The vehicle control, positive control, ABLEC 0.02%, and ABLEC 0.04% groups showed significantly lower IL-22 concentrations than the untreated AD control (adjusted p = 0.024 for each). However, none of the ABLEC groups differed significantly from the vehicle control, indicating that an extract-specific effect could not be demonstrated. Filaggrin expression did not differ significantly among groups (p = 0.547; ω 2 = 0.000).
CONCLUSION: ABLEC at 0.02% and 0.04% were associated with lower cutaneous IL-22 concentrations than the untreated AD control, but similar reductions in the vehicle control precluded demonstration of an extract-specific effect. Furthermore, no statistically detectable difference in filaggrin expression or dose-response relationship was observed.